Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies

Laura A. Marlow, Christina A. von Roemeling, Simon J. Cooper, Yilin Zhang, Stephen D. Rohl, Shilpi Arora, Irma M. Gonzales, David O. Azorsa, Honey V. Reddi, Han W Tun, Heike R. Dö ppler, Peter Storz, Robert Christian Smallridge, John A III Copland

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth through transcriptional regulation of key genes regulating cell cycle arrest and apoptosis. In many types of cancer, in response to growth factor signaling, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Here we show that FoxO3a remains nuclear in anaplastic thyroid carcinoma (ATC). This correlates with lack of Akt phosphorylation at serine473 in ATC cell lines and tissues of ATC patients, providing a potential explanation for nuclear FoxO3a. Mechanistically, nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. Silencing FoxO3a with a reverse genetics approach leads to downregulation of CCNA1 mRNA and protein. These combined data suggest an entirely novel function for FoxO3a in ATC promotion by enhancing cell cycle progression and tumor growth through transcriptional upregulation of cyclin A1. This is clinically relevant since we detected highly elevated CCNA1 mRNA and protein levels in tumor tissues of ATC patients. Our data indicate therapeutic inactivation of FoxO3a may lead to attenuation of tumor expansion in ATC. This new paradigm also suggests caution in relation to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways.

Original languageEnglish (US)
Pages (from-to)4253-4263
Number of pages11
JournalJournal of Cell Science
Volume125
Issue number18
DOIs
StatePublished - 2012

Fingerprint

Cyclin A1
Neoplasms
Therapeutics
Cell Cycle
Up-Regulation
Forkhead Transcription Factors
Reverse Genetics
Messenger RNA
Growth
Cell Cycle Checkpoints
Anaplastic Thyroid Carcinoma
Intercellular Signaling Peptides and Proteins
Proteins
Down-Regulation
Phosphorylation
Apoptosis
Cell Line

Keywords

  • Anaplastic thyroid carcinoma
  • Cyclin A1
  • FoxO3a
  • Transcriptional regulation

ASJC Scopus subject areas

  • Cell Biology

Cite this

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1 : A paradigm shift that impacts current therapeutic strategies. / Marlow, Laura A.; von Roemeling, Christina A.; Cooper, Simon J.; Zhang, Yilin; Rohl, Stephen D.; Arora, Shilpi; Gonzales, Irma M.; Azorsa, David O.; Reddi, Honey V.; Tun, Han W; Dö ppler, Heike R.; Storz, Peter; Smallridge, Robert Christian; Copland, John A III.

In: Journal of Cell Science, Vol. 125, No. 18, 2012, p. 4253-4263.

Research output: Contribution to journalArticle

Marlow, Laura A. ; von Roemeling, Christina A. ; Cooper, Simon J. ; Zhang, Yilin ; Rohl, Stephen D. ; Arora, Shilpi ; Gonzales, Irma M. ; Azorsa, David O. ; Reddi, Honey V. ; Tun, Han W ; Dö ppler, Heike R. ; Storz, Peter ; Smallridge, Robert Christian ; Copland, John A III. / Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1 : A paradigm shift that impacts current therapeutic strategies. In: Journal of Cell Science. 2012 ; Vol. 125, No. 18. pp. 4253-4263.
@article{3495aa0e0d9a4761bbd8f0943f9ad279,
title = "Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies",
abstract = "The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth through transcriptional regulation of key genes regulating cell cycle arrest and apoptosis. In many types of cancer, in response to growth factor signaling, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Here we show that FoxO3a remains nuclear in anaplastic thyroid carcinoma (ATC). This correlates with lack of Akt phosphorylation at serine473 in ATC cell lines and tissues of ATC patients, providing a potential explanation for nuclear FoxO3a. Mechanistically, nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. Silencing FoxO3a with a reverse genetics approach leads to downregulation of CCNA1 mRNA and protein. These combined data suggest an entirely novel function for FoxO3a in ATC promotion by enhancing cell cycle progression and tumor growth through transcriptional upregulation of cyclin A1. This is clinically relevant since we detected highly elevated CCNA1 mRNA and protein levels in tumor tissues of ATC patients. Our data indicate therapeutic inactivation of FoxO3a may lead to attenuation of tumor expansion in ATC. This new paradigm also suggests caution in relation to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways.",
keywords = "Anaplastic thyroid carcinoma, Cyclin A1, FoxO3a, Transcriptional regulation",
author = "Marlow, {Laura A.} and {von Roemeling}, {Christina A.} and Cooper, {Simon J.} and Yilin Zhang and Rohl, {Stephen D.} and Shilpi Arora and Gonzales, {Irma M.} and Azorsa, {David O.} and Reddi, {Honey V.} and Tun, {Han W} and {D{\"o} ppler}, {Heike R.} and Peter Storz and Smallridge, {Robert Christian} and Copland, {John A III}",
year = "2012",
doi = "10.1242/jcs.097428",
language = "English (US)",
volume = "125",
pages = "4253--4263",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "18",

}

TY - JOUR

T1 - Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1

T2 - A paradigm shift that impacts current therapeutic strategies

AU - Marlow, Laura A.

AU - von Roemeling, Christina A.

AU - Cooper, Simon J.

AU - Zhang, Yilin

AU - Rohl, Stephen D.

AU - Arora, Shilpi

AU - Gonzales, Irma M.

AU - Azorsa, David O.

AU - Reddi, Honey V.

AU - Tun, Han W

AU - Dö ppler, Heike R.

AU - Storz, Peter

AU - Smallridge, Robert Christian

AU - Copland, John A III

PY - 2012

Y1 - 2012

N2 - The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth through transcriptional regulation of key genes regulating cell cycle arrest and apoptosis. In many types of cancer, in response to growth factor signaling, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Here we show that FoxO3a remains nuclear in anaplastic thyroid carcinoma (ATC). This correlates with lack of Akt phosphorylation at serine473 in ATC cell lines and tissues of ATC patients, providing a potential explanation for nuclear FoxO3a. Mechanistically, nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. Silencing FoxO3a with a reverse genetics approach leads to downregulation of CCNA1 mRNA and protein. These combined data suggest an entirely novel function for FoxO3a in ATC promotion by enhancing cell cycle progression and tumor growth through transcriptional upregulation of cyclin A1. This is clinically relevant since we detected highly elevated CCNA1 mRNA and protein levels in tumor tissues of ATC patients. Our data indicate therapeutic inactivation of FoxO3a may lead to attenuation of tumor expansion in ATC. This new paradigm also suggests caution in relation to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways.

AB - The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth through transcriptional regulation of key genes regulating cell cycle arrest and apoptosis. In many types of cancer, in response to growth factor signaling, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Here we show that FoxO3a remains nuclear in anaplastic thyroid carcinoma (ATC). This correlates with lack of Akt phosphorylation at serine473 in ATC cell lines and tissues of ATC patients, providing a potential explanation for nuclear FoxO3a. Mechanistically, nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. Silencing FoxO3a with a reverse genetics approach leads to downregulation of CCNA1 mRNA and protein. These combined data suggest an entirely novel function for FoxO3a in ATC promotion by enhancing cell cycle progression and tumor growth through transcriptional upregulation of cyclin A1. This is clinically relevant since we detected highly elevated CCNA1 mRNA and protein levels in tumor tissues of ATC patients. Our data indicate therapeutic inactivation of FoxO3a may lead to attenuation of tumor expansion in ATC. This new paradigm also suggests caution in relation to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways.

KW - Anaplastic thyroid carcinoma

KW - Cyclin A1

KW - FoxO3a

KW - Transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=84872188837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872188837&partnerID=8YFLogxK

U2 - 10.1242/jcs.097428

DO - 10.1242/jcs.097428

M3 - Article

C2 - 22718346

AN - SCOPUS:84872188837

VL - 125

SP - 4253

EP - 4263

JO - Journal of Cell Science

JF - Journal of Cell Science

SN - 0021-9533

IS - 18

ER -